A Novel Combination Therapy Approach for the Treatment of Acute Myeloid Leukemia: The Multi-Kinase Inhibitor Sorafenib and the HDM2 Inhibitor Nutlin-3

Haematologica - Italy
doi 10.3324/haematol.2012.078451
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Clinical Experience With the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies

American Journal of Hematology
Hematology
2017English

Effects of the Multi‐kinase Inhibitor Midostaurin in Combination With Chemotherapy in Models of Acute Myeloid Leukaemia

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2020English

A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia

Frontiers in Pharmacology
Pharmacology
2019English

Combination Treatment of an IDH1 Inhibitor With Chemotherapy in IDH1 Mutant Acute Myeloid Leukemia

Annals of Hematology
MedicineHematology
2020English

The Sorafenib Plus Nutlin-3 Combination Promotes Synergistic Cytotoxicity in Acute Myeloid Leukemic Cells Irrespectively of FLT3 and P53 Status

Haematologica
Hematology
2012English

Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 Against Human Acute Myelogenous Leukemia Cells With Mutant FLT-3

Clinical Cancer Research
Cancer ResearchOncology
2004English

Managing Chronic Myeloid Leukemia Patients Intolerant to Tyrosine Kinase Inhibitor Therapy

Blood Cancer Journal
OncologyHematology
2012English

MDM2 Inhibitor, Nutlin 3a, Induces P53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation

PLoS ONE
Multidisciplinary
2015English

Frequent Loss of RAF Kinase Inhibitor Protein Expression in Acute Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy